42152-55-6

Usage

Uses

Used in Pharmaceutical Development:
N-(5-CHLORO-THIOPHEN-2-YL)-ACETAMIDE is used as a potential candidate in pharmaceutical development for its structural similarity to biologically active molecules, which may contribute to the creation of new drugs.
Used in Neurological Disorders Treatment:
In the field of medicine, specifically neurology, N-(5-CHLORO-THIOPHEN-2-YL)-ACETAMIDE is considered for use as a therapeutic agent for neurological disorders, given its potential to interact with biological targets relevant to such conditions.
Used as a Potential Analgesic:
N-(5-CHLORO-THIOPHEN-2-YL)-ACETAMIDE is also used as a potential analgesic, suggesting its capacity to alleviate pain, possibly due to its structural features that allow it to engage with pain-signaling pathways in the body.
Further Research Applications:
N-(5-CHLORO-THIOPHEN-2-YL)-ACETAMIDE is used in research settings to explore its potential therapeutic properties and biological activities, with the aim of understanding its full scope of applications and effects in medical and pharmaceutical contexts.

InChI:InChI=1/C6H6ClNOS/c1-4(9)8-6-3-2-5(7)10-6/h2-3H,1H3,(H,8,9)

Upstream product

• 97799-95-6 5-chloro-2-acetylthiophene oxime benzenesulfonate 
• 7647-01-0 hydrogenchloride 
• 598-49-2 N-chloroacetamide 
• 42520-87-6 C₆H₆ClNOS 
• 63806-71-3 (5-chloro-thiophen-2-yl)-carbamic acid tert-butyl ester 
• 108-24-7 acetic anhydride 
• 42520-87-6 (E)-1-(5-chlorothiophen-2-yl)ethan-1-one oxime 

Downstream Products

• 679794-81-1 N-(5-chloro-3-formyl-2-thienyl) acetamide 
• 679794-83-3 methyl N-acetyl-N-(5-chloro-3-formyl-2-thienyl)glycinate 
• 1353894-34-4 2,6-dichlorothieno[2,3-b]pyridine-5-carbaldehyde 

Relevant academic research and scientific papers

Development of thiophenic analogues of benzothiadiazine dioxides as new powerful potentiators of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptors

On the basis of the results obtained in previous series of AMPA potentiators belonging to 3,4-dihydro-2H-benzo- and 3,4-dihydro-2H-pyrido-1,2,4- thiadiazine 1,1-dioxides, the present work focuses on the design of original isosteric 3,4-dihydro-2H-thieno-1,2,4-thiadiazine 1,1-dioxides. Owing to the sulfur position, three series of compounds were developed and their activity as AMPA potentiators was characterized. In each of the developed series, potent compounds were discovered. After screening the selected active compounds on a safety in vivo test, 6-chloro-4-ethyl-3,4-dihydro-2H-thieno[2,3-e]-1,2,4- thiadiazine 1,1-dioxide (24) appeared as the most promising compound and was further evaluated. Its effects on long-term potentiation in vivo and on AMPA-mediated noradrenaline release were measured to predict its potential cognitive enhancing properties. Finally, an object recognition test performed in mice revealed that 24 was able to significantly enhance cognition, after oral administration, at doses as low as 0.3 mg/kg. This study validates the interest of the isosteric replacement of the benzene or pyridine nuclei by the thiophene nucleus in the ring-fused thiadiazine dioxides class of AMPA potentiators.

HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Novel thienopyrrole glycogen phosphorylase inhibitors: Synthesis, in vitro SAR and crystallographic studies

Two series of novel thienopyrrole inhibitors of recombinant human liver glycogen phosphorylase a (GPa) which are effective in reducing glucose output from rat hepatocytes are described. Representative compounds have been shown to bind at the dimer interface site of the rabbit muscle enzyme by X-ray crystallography.

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF THE THIENOPYRROLE DERIVATIVES

A process for preparing a compound of formula (I) where R4 and R5are as defined in the specification; and R6 is hydrogen or a protecting group, which process comprises cyclisation of a compound of formula (II) where R4, R5and R6 are as defined in relation to formula (I) and R7is a nitrogen-protecting group, and removing protecting group R7-, and thereafter if desired or necessary, removing any protecting group R6 to obtain the corresponding carboxylic acid. Novel intermediates and the use of the products in the preparation of pharmaceutical compounds is also described and claimed

BECKMANN REARRANGEMENT OF ACETYLTHIOPHENE OXIME BENZENESULFONATES AS A METHOD FOR THE SYNTHESIS OF ACETAMIDOTHIOPHENES

The Beckmann rearrangement of 2-acetylthiophene, 5-methyl-2-acetylthiophene, 5-chloro-2-acetylthiophene, and 2,5-dichloro-3-acetylthiphene oxime benzenesulfonates to the corresponding acetamidothiophenes was carried out by heating with an aqueous methanol solution of sodium acetate.This method can be used for the preparative synthesis of 2-acetamidothiophene and 2,5-dichloro-3-acetamidothiophene.